These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 30535471)
1. MicroRNA-497 inhibits multiple myeloma growth and increases susceptibility to bortezomib by targeting Bcl-2. Tian F; Zhan Y; Zhu W; Li J; Tang M; Chen X; Jiang J Int J Mol Med; 2019 Feb; 43(2):1058-1066. PubMed ID: 30535471 [TBL] [Abstract][Full Text] [Related]
2. Study on the Association Between miRNA-202 Expression and Drug Sensitivity in Multiple Myeloma Cells. Shen X; Guo Y; Qi J; Shi W; Wu X; Ni H; Ju S Pathol Oncol Res; 2016 Jul; 22(3):531-9. PubMed ID: 26689580 [TBL] [Abstract][Full Text] [Related]
3. Ectopic expression of BIRC5-targeting miR-101-3p overcomes bone marrow stroma-mediated drug resistance in multiple myeloma cells. Abdi J; Rastgoo N; Chen Y; Chen GA; Chang H BMC Cancer; 2019 Oct; 19(1):975. PubMed ID: 31638931 [TBL] [Abstract][Full Text] [Related]
4. miR-520g and miR-520h overcome bortezomib resistance in multiple myeloma via suppressing APE1. Yuan X; Ma R; Yang S; Jiang L; Wang Z; Zhu Z; Li H Cell Cycle; 2019 Jul; 18(14):1660-1669. PubMed ID: 31204563 [No Abstract] [Full Text] [Related]
5. MicroRNA-19a functions as an oncogene by regulating PTEN/AKT/pAKT pathway in myeloma. Zhang X; Chen Y; Zhao P; Zang L; Zhang Z; Wang X Leuk Lymphoma; 2017 Apr; 58(4):932-940. PubMed ID: 27830963 [TBL] [Abstract][Full Text] [Related]
6. hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10. Xi H; Li L; Du J; An R; Fan R; Lu J; Wu YX; Wu SX; Hou J; Zhao LM Oncol Rep; 2017 Feb; 37(2):961-968. PubMed ID: 28000886 [TBL] [Abstract][Full Text] [Related]
7. Effects of arsenic trioxide alone and in combination with bortezomib in multiple myeloma RPMI 8266 cells. Elmahi AY; Niu C; Li W; Li D; Wang GJ; Hao SS; Cui JW Asian Pac J Cancer Prev; 2013; 14(11):6469-73. PubMed ID: 24377552 [TBL] [Abstract][Full Text] [Related]
8. Enhanced antitumor effect of combination of annexin A1 knockdown and bortezomib treatment in multiple myeloma in vitro and in vivo. Jia C; Kong D; Guo Y; Li L; Quan L Biochem Biophys Res Commun; 2018 Nov; 505(3):720-725. PubMed ID: 30292410 [TBL] [Abstract][Full Text] [Related]
9. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity. Que W; Chen J; Chuang M; Jiang D APMIS; 2012 Mar; 120(3):195-203. PubMed ID: 22339676 [TBL] [Abstract][Full Text] [Related]
11. Decitabine enhances bortezomib treatment in RPMI 8226 multiple myeloma cells. Cao Y; Qiu GQ; Wu HQ; Wang ZL; Lin Y; Wu W; Xie XB; Gu WY Mol Med Rep; 2016 Oct; 14(4):3469-75. PubMed ID: 27571872 [TBL] [Abstract][Full Text] [Related]
12. MiR-31 regulates the cisplatin resistance by targeting Src in gallbladder cancer. Li M; Chen W; Zhang H; Zhang Y; Ke F; Wu X; Zhang Y; Weng M; Liu Y; Gong W Oncotarget; 2016 Dec; 7(50):83060-83070. PubMed ID: 27825112 [TBL] [Abstract][Full Text] [Related]
13. MicroRNA-324-5p regulates stemness, pathogenesis and sensitivity to bortezomib in multiple myeloma cells by targeting hedgehog signaling. Tang B; Xu A; Xu J; Huang H; Chen L; Su Y; Zhang L; Li J; Fan F; Deng J; Tang L; Sun C; Hu Y Int J Cancer; 2018 Jan; 142(1):109-120. PubMed ID: 28905994 [TBL] [Abstract][Full Text] [Related]
14. Lnc NEAT1/miR-29b-3p/Sp1 form a positive feedback loop and modulate bortezomib resistance in human multiple myeloma cells. Che F; Ye X; Wang Y; Ma S; Wang X Eur J Pharmacol; 2021 Jan; 891():173752. PubMed ID: 33253679 [TBL] [Abstract][Full Text] [Related]
15. MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma. Du J; Liu S; He J; Liu X; Qu Y; Yan W; Fan J; Li R; Xi H; Fu W; Zhang C; Yang J; Hou J Oncotarget; 2015 Jun; 6(17):14993-5007. PubMed ID: 25915427 [TBL] [Abstract][Full Text] [Related]
16. LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p. Pan Y; Zhang Y; Liu W; Huang Y; Shen X; Jing R; Pu J; Wang X; Ju S; Cong H; Chen H Cell Death Dis; 2019 Feb; 10(2):106. PubMed ID: 30728351 [TBL] [Abstract][Full Text] [Related]
17. CircRNA ITCH increases bortezomib sensitivity through regulating the miR-615-3p/PRKCD axis in multiple myeloma. Liu J; Du F; Chen C; Li D; Chen Y; Xiao X; Hou X Life Sci; 2020 Dec; 262():118506. PubMed ID: 33031827 [TBL] [Abstract][Full Text] [Related]
18. Bortezomib promotes apoptosis of multiple myeloma cells by regulating HSP27. Li J; Zhang X; Shen J; Guo J; Wang X; Liu J Mol Med Rep; 2019 Sep; 20(3):2410-2418. PubMed ID: 31322176 [TBL] [Abstract][Full Text] [Related]
19. The MIP-1α autocrine loop contributes to decreased sensitivity to anticancer drugs. Tsubaki M; Takeda T; Tomonari Y; Mashimo K; Koumoto YI; Hoshida S; Itoh T; Imano M; Satou T; Sakaguchi K; Nishida S J Cell Physiol; 2018 May; 233(5):4258-4271. PubMed ID: 29057477 [TBL] [Abstract][Full Text] [Related]
20. miR-20a induces cisplatin resistance of a human gastric cancer cell line via targeting CYLD. Zhu M; Zhou X; Du Y; Huang Z; Zhu J; Xu J; Cheng G; Shu Y; Liu P; Zhu W; Wang T Mol Med Rep; 2016 Aug; 14(2):1742-50. PubMed ID: 27357419 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]